The generic name of Vivanxin is Chlorphenazolate Soft Capsules, which is mainly used for the treatment of hereditary transthyretin amyloidosis cardiomyopathy and other diseases, usually requires long-term use of medication, and the effect of short-term use is not clear. Chlorphenesinic acid is a specific stabilizer of transthyretin protein, whether it is effective or not needs to be based on whether it is for the indications of the drug, the course of treatment and whether the dosage is up to the standard and other comprehensive analysis, and at the same time need to pay attention to contraindications. 1. Indications: mainly used for the treatment of adult wild-type, genetic type and other transthyretin amyloidosis caused by myocardial injury disease. 2. Duration of use: The average duration of use covered by the drug’s dosing guidelines is 24.5 months; it has also been mentioned in the literature that transthyretin protein levels have gradually stabilized in some populations at 6 weeks of use. No short duration of dosing has been reported. 3. Contraindications are as follows: (1) Chlorphenesinic acid and other drug components are contraindicated in case of allergy. (2) Not recommended during pregnancy and planned pregnancy. (3) It is contraindicated during lactation or if breastfeeding is discontinued during the administration of the drug. The drug needs to be used under the guidance of a clinician and unauthorized use is prohibited.